Rabeprazole Injection IP, marketed as Satmorab-IV, is a potent intravenous medication used primarily for treating severe gastroesophageal reflux disease (GERD) and gastric ulcers. It belongs to the proton pump inhibitor class, effectively suppressing gastric acid secretion to alleviate symptoms such as heartburn and acid reflux. Satmorab-IV offers rapid onset of action, making it valuable in acute settings where oral therapy is not feasible. It ensures quick relief and management of acid-related gastrointestinal disorders.Available in PCD Franchise for injectable range and third party manufacturing.